Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.44 |
| ▸ | CDK1 | P06493 | 5/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248788 | 0.97 | CDK2 (0.48) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL14889685 | 0.93 | CDK2 (0.40) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL23021957 | 0.84 | HRH3 (0.45) | — | |
| SCHEMBL3136710 | 0.82 | HTR2B (0.43) | — | |
| SCHEMBL3250575 | 0.78 | CNR2 (0.40) | — | |
| SCHEMBL3141781 | 0.77 | JAK3 (0.35) | MCHR1 | |
| SCHEMBL16446538 | 0.76 | CDK2 (0.45) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL28163722 | 0.75 | CDK2 (0.39) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL3252255 | 0.75 | CNR2 (0.42) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL29597929 | 0.72 | CCR4 (0.42) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076499-B1 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-7691863-B2 | Pyrazine-2-carboxamide derivatives as CB2 receptor modulators | HOFFMAN-LA ROCHE INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2076499-A2 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20080085905-A1 | Pyrazine-2-carboxamide derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | disclosed |
| WO-2008040649-A2 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085905-A1 | Pyrazine-2-carboxamide derivatives | CNR2, CNR1, P2RY2 | CDK2 431/4885CCNA2 910/4885CCNA1 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.